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▼Allele specific restriction analysis (ASRA) represents a
rapid PCR-based screening method to detect point mu-
tations at defined codons without the necessity of han-
dling hazardous radioisotopes (Ref. 1). If a constitu-
tional restriction-enzyme cleavage site comprises the target
codon, specific DNA sequences are simply preamplified be-
fore a reamplification step with a nested primer in order
to avoid unspecific by-products. Alternatively, a mismatch
primer that induces an artificial restriction site within the
target codon can be used in the reamplification step. In both
systems, a mutated allele will eliminate the restriction site.
Consequently, after cleavage of the reamplification product
and subsequent agarose gel electrophoresis, a point muta-
tion can be visualized by ethidium bromide fluorescence
as a persistent undigested fragment, along with a digested
fragment corresponding to the normal allele. In practice,
however, ASRA shows certain limitations.
Tissue samples of tumours or potential tumour precur-
sors frequently constitute a mixture of unaffected and
mutation-carrying cells in various ratios for two main rea-
sons. First, surgically removed lesions sometimes contain
only aminor fraction of pathological cells, because the spec-
imen is: a) contaminated by normal cells from surround-
ing tissue; and/or b) infiltrated by lymphocytes and blood
vessels. Second, only a small fraction of the pathological
cells might harbour the mutated allele (tumour subpopu-
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lations). Such minor constituents often yield very faint or
almost invisible persistent fragments in ASRA. Frequently in
these cases, mutations cannot be characterized by the sub-
sequent sequencing of the amplification product, because
the mutagenic nucleotide exchange is blotted out by un-
specific sequence signals. Extremely faint residual mutation
bands in ASRA are indistinguishable even from incomplete
restriction-enzyme cleavage of normal alleles and, there-
fore, it is impossible to decide if the corresponding sample
carries a mutation.
When ASRA is combined with single-strand
conformation polymorphism (SSCP) analysis, this problem
can be solved, because only real mutations can produce
variations in band migration patterns in SSCP gels (faint,
abnormal silver-stained electrophoresis bands). Further-
more, if it is once verified by initial combined ASRA/SSCP
analysis that SSCP analysis is able to detect a specific muta-
tion in a certain preamplification product, further samples
can be investigated by SSCP analysis alone. Compared
with ASRA, SSCP analysis is more sensitive (silver-stained
polyacrylamide gels), less time-consuming (no restriction
enzyme cleavage) and generally less expensive (the high
prices of certain restriction enzymes). In addition, all mu-
tated alleles can be reamplified if necessary (enrichment of
the mutated allele). Finally, the corresponding mutations
can be characterized unambiguously by sequencing.
As an example, standardised SSCP analysis (high re-
producibility) of exon 2 of the human N-ras gene
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FIGURE 1. Exon 2 of the gene encoding human N-ras with amplification primers (N5‘61 and N3‘61) and mismatch primer (N61mA), with
corresponding artificially created Mlu NI (MscI) restriction site (tgg!cCA). Transversion of CAA (Gln) to AAA (Lys) in the first position of codon 61, as
well as CAA (Gln) to CGA (Arg) transition in the second position, eliminates the artificial restriction site and leads to an undigested 85 bp fragment,
which corresponds to the mutated allele.
(preamplification) was coupled with mismatch primer-
based ASRA of codon 61 (for template sequence, primers
and restriction sites see Fig. 1). All mutations indicated by
ASRA (persistent undigested fragments) (Fig. 2a, see arrow)
could be confirmed by parallel SSCP analysis (aberrantly
migrating bands) (Fig. 2b, see arrow). The intensity of mu-
tation carrying bands correlated in ASRA and SSCP gels.
Because of the superior detection sensitivity of the SSCP
technique, real mutations could easily be distinguished
from incomplete restriction-enzyme cleavage by compar-
ative examination of ASRA and SSCP gels (Fig. 2). Owing to
the reamplification of the aberrantly migrating SSCP bands,
all mutations could be exactly characterized by sequencing
(see Fig. 3).
In principle, SSCP analysis can be combined with ASRA
for improved point-mutation screening in H-ras, K-ras
and N-ras genes at codons 12, 13 and 61 (Ref. 2) as well
as in any oncogene that is activated by somatic point
mutations [e.g. TRK (Ref. 3), TSHR (Ref. 4), CDK4 (Ref. 5),
GSP, GIP2 (Ref. 6) MET (Ref. 7), TC21, R-ras3 (Ref. 8), KIT
(Ref. 9)].
Furthermore, combined ASRA/SSCP analysis can facili-
tate the creation of improved mutation-screening strategies
in prenatal diagnosis, in cases where distinct amino acid
exchanges (germline mutations) produce specific disease-
related alleles (Ref. 10).
Protocol
General PCR conditions:
All PCR reactions were performed in a 100 µl volume, ac-
cording to standardized basic conditions (Ref. 11) contain-
ing: 50 mM KCl; 10 mM Tris-HCl (pH 8.4 at room tempera-
ture); 1.5 mM MgCl2; 100 µg/ml gelatine; 200 µM of each
deoxynucleotide triphosphate (dATP, dCTP, dGTP, dTTP);
and 2.5 units of Taq polymerase. DNA samples were de-
natured at 95◦C for 3 minutes, cycled 30 × at 94◦C for
1 minute, 55◦C for 1 minute, 72◦C for 1 minute, and finally
incubated at 72◦C for 5 minutes in a DNA thermal cycler
(Perkin-Elmer).
Preamplification
0.1 µg of the genomic DNA was amplified with 300 ng
of N5‘61 (sense primer) and N3‘61 (antisense primer),
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FIGURE 2. Parallel comparative analysis of ethidium bromide-stained
ASRA gel (a) and silver-stained SSCP gel (b). These comprise ten
different melanocytic lesions (in the same order), harbouring dominant
mutations in N-ras Codon 61 along with amnion DNA samples as a
negative control (A) and a 50 bp / 100 bp ladder as size standard (M) in
(a) and (b), respectively. The undigested reamplification product serves
as a positive control (PC) in (a). The intensity of the mutation carrying
bands (indicated by an arrow) correlates in both methods. Because of
the superior detection sensitivity of the SSCP technique, real mutations
could be distinguished easily from uncomplete restriction-enzyme
cleavage by comparative examination of ASRA and SSCP gels (see
lesions 5, 6 and 7). On the SSCP gel, lesion 10 exhibits an aberrant
migrating band differing from all other samples (indicating a different
point mutation). No aberrant migrating band is visible in the first
amnion sample, which exhibits uncomplete cleavage in ASRA.
respectively. 10 µl of the preamplification solution was
resolved on a 2% agarose gel and visualized by ethidium
bromide fluorescence (quality control, data not shown).
The amplification product was excised with a sterile scalpel
and dissolved in 500 µl of distilled water overnight at 4◦C.
Reamplification (ASRA)
10 µl of the purified preamplification product was reampli-
fied (20 cycles) with 300 ng of N61mA (mismatch primer)
and N3‘61, respectively. 10 µl of the reamplification prod-
uct was analysed on a 2% agarose gel (quality control,
data not shown). 15 µl of the reamplification product was
digested with 10 units Mlu NI (Boehringer Mannheim)
an isoschizomer of MscI and finally analysed by gel elec-
trophoresis (Fig. 2a) on a 3.5% NuSieve 1% agarose gel. In
the case of a dominant mutation, a part of the 85 bp frag-
ment will become indigestible.
SSCP analysis
For SSCP analysis (Fig. 2b) 4 µl of the preamplification prod-
uct are mixed with 4 µl of SSCP buffer (2mM EDTA, 0.005%
bromophenol blue, 0.005% xylene cyanol in deionized for-
mamide) and incubated in the thermal cycler for 10 min-
utes at 98 ◦C prior to cooling for 10 minutes in an ice wa-
ter bath. Samples are applied to a commercially available
10% polyacrylamide gel Clean Gel, (Pharmacia) on a Multi-
phor II horizontal electrophoresis chamber (Pharmacia) at
4 ◦C using the PCR Fragment Analysis Kit (Pharmacia). Elec-
trophoresis and silver staining was performed as described
by the manufacturer.
Mutant allele enrichment PCR
The aberrantly migrating SSCP band is excised with sterile
scissors and incubated at different temperatures in 100 µl
distilled water (5 minutes at 95 ◦C, 20 minutes at 65 ◦C, 30
minutes at 20 ◦C, storage at 8 ◦C). 5−20 µl of this solution
are reamplified under preamplification reaction conditions,
which selects for the mutant allele against the normal one.
Sequencing
The exact type and position of detectedmutations was char-
acterized by subsequent sequencing of the preamplification
product and the mutant allele enrichment PCR product, re-
spectively (Fig. 3a,b): PCR products were purified using the
High Pure PCR Purification Kit (Boehringer, Mannheim).
7.5 µl of purified PCR product were cycle-sequenced with
the Sequi Term EXCEL DNA Sequencing Kit (Epicentre
Technologies) using 3 pmoles of a 5’-biotin ylated N5‘61
primer (Pharmacia). The sequences were resolved on 6%
polyacrylamide-urea gels in Tris-borate-ethylenediamine-
tetraacetate buffer (30 mM, pH 8.0). DNA sequences were
characterized by using the Sequenase Images, Non-Isotopic
DNA Sequencing System (United States Biochemical), based
on chemiluminescence detection.
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FIGURE 3. Sequence of the preamplification product (a) and the mutant allele enrichment PCR product (b). The mutation in lesions 1 to 9 (CAA to
AAA transversion) could only be determined after mutant allele enrichment PCR (see arrow). Lesion 10 harbours a CAA to CGA transition.
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Products Used
DNA thermal cycler 480: DNA thermal cycler 480
from PE Applied Biosystems
DNA thermal cycler 480: DNA thermal cycler 480
from PE Applied Biosystems
Thermal Cycler: Thermal Cycler from Techne
(Cambridge) Ltd
thermal cycler: thermal cycler from MJ Research
Inc
Mlu NI: Mlu NI from Boehringer Mannheim
CleanGel: CleanGel from Pharmacia
Acrylamide: Acrylamide from Sigma
Multiphor II: Multiphor II from Pharmacia
PCR Fragment Analysis Kit: PCR Fragment Anal-
ysis Kit from Pharmacia
PCR clean-up system: PCR clean-up system from
QIAGEN GmbH
biotin: biotin from Boehringer Mannheim
Sequenase: Sequenase from Amersham Pharmacia
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